Drug resistance mutations and heteroresistance detected using the GenoType MTBDRplus assay and their implication for treatment outcomes in patients from Mumbai, India

BMC Infectious Diseases

Volumn 12, Issue , 2012, Pages

  Tolani, Monica P ^a   D'souza, Desiree T B ^a   Mistry, Nerges F ^a  

^a FOUNDATION FOR MEDICAL RESEARCH   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GENE; BACTERIAL LOAD; BACTERIAL MUTATION; BACTERIUM ISOLATION; BIOASSAY; CONTROLLED STUDY; INDIA; INHA GENE; INTERMETHOD COMPARISON; KATG GENE; MULTIDRUG RESISTANCE; MULTIDRUG RESISTANT TUBERCULOSIS; MUTATIONAL ANALYSIS; NONHUMAN; OUTCOME ASSESSMENT; PHENOTYPE; RNA POLYMERASE BETA SUBUNIT GENE; WILD TYPE; ADOLESCENT; ADULT; AGED; DRUG EFFECT; EVALUATION; GENETICS; GENOTYPE; HUMAN; ISOLATION AND PURIFICATION; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; MIDDLE AGED; MISSENSE MUTATION; MYCOBACTERIUM TUBERCULOSIS; TIME; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTITUBERCULAR AGENTS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; GENOTYPE; HUMANS; INDIA; ISONIAZID; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MUTATION, MISSENSE; MYCOBACTERIUM TUBERCULOSIS; RIFAMPIN; TIME FACTORS; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT; YOUNG ADULT;

EID: 84856018569     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-12-9     Document Type: Article

References (49)

1. World Health Organisation Multidrug and extensively drug-resistant TB (M/XDR-TB): 2010 Global report on surveillance and response. 2010, WHO/HTM/TB/2010.3, World Health Organisation.
2. Albert H, Bwanga F, Mukkada S, Nyesiga B, Ademun JP, Lukyamuzi G, Haile M, Hoffner S, Joloba M, O'Brien R. Rapid screening of MDR-TB using molecular Line Probe Assay is feasible in Uganda. BMC Infect Dis 2010, 10:41. 10.1186/1471-2334-10-41, 2841659, 20187922.
3. World Health Organisation Policy statement. Molecular line probe assays for rapid screening of patients at risk of multi-drug resistant TB (MDR-TB). 2008, World Health Organisation., http://www.who.int/tb/laboratory/lpa_policy.pdf
4. Watterson SA, Wilson SM, Yates MD, Drobniewski FA. Comparison of three molecular assays for rapid detection of rifampin resistance in Mycobacterium tuberculosis. J Clin Microbiol 1998, 36:1969-1973. 104962, 9650946.
5. de Beenhouwer HZ, Hiang L, Jannes G, Mijs W, Machtelinckx L, Rossau R, Traore H, Portaels F. Rapid detection of rifampicin resistance in sputum and biopsy specimens from tuberculosis patients by PCR and line probe assay. Tuber Lung Dis 1995, 76:425-430. 10.1016/0962-8479(95)90009-8, 7496004.
6. Telenti A, Imboden P, Marchesi F, Lowrie D, Cole ST, Colston MJ, Matter L, Schopfer K, Bodmer T. Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis. Lancet 1993, 341:647-650. 10.1016/0140-6736(93)90417-F, 8095569.
7. Zhang M, Yue J, Yang YP, Zhang HM, Lei JO, Jin RL, Zhang XL, Wang HH. Detection of mutations associated with isoniazid resistance in Mycobacterium tuberculosis isolates from China. J Clin Microbiol 2005, 43:5477-5482. 10.1128/JCM.43.11.5477-5482.2005, 1287806, 16272473.
8. Ramaswamy SV, Reich R, Dou SJ, Jasperse L, Pan X, Wanger A, Quitugua T, Graviss EA. Single nucleotide polymorphisms in genes associated with isoniazid resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother 2003, 47:1241-1250. 10.1128/AAC.47.4.1241-1250.2003, 152487, 12654653.
9. Huyen MNT, Tiemersma EW, Lan NTN, Cobelens FGJ, Dung NH, Sy DN, Buu TN, Kremer K, Hang PT, Caws M, et al. Validation of the GenoType® MTBDRplus assay for diagnosis of multidrug resistant tuberculosis in South Vietnam. BMC Infect Dis 2010, 10:149. 10.1186/1471-2334-10-149, 2901356, 20525271.
10. Barnard M, Albert H, Coetzee G, O'Brien R, Bosman ME. Rapid molecular screening for multidrug-resistant tuberculosis in a high-volume public health laboratory in South Africa. Am J Respir Crit Care Med 2008, 177:787-792. 10.1164/rccm.200709-1436OC, 18202343.
11. Pym AS, Saint-Joanis B, Cole ST. Effect of katG mutations on the virulence of Mycobacterium tuberculosis and the implication for transmission in humans. Infect Immun 2002, 70:4955-4960. 10.1128/IAI.70.9.4955-4960.2002, 128294, 12183541.
12. Bartfai Z, Somoskovi A, Kodmon C, Szabo N, Puskas E, Kosztolanyi L, Farago E, Mester J, Parsons LM, Salfinger M. Molecular characterization of rifampin-resistant isolates of Mycobacterium tuberculosis from Hungary by DNA sequencing and the line probe assay. J Clin Microbiol 2001, 39:3736-3739. 10.1128/JCM.39.10.3736-3739.2001, 88421, 11574605.
13. Rinder H, Dobner P, Feldmann K, Rifai M, Bretzel G, Rusch-Gerdes S, Loscher T. Disequilibria in the distribution of rpoB alleles in rifampicin-resistant M. tuberculosis isolates from Germany and Sierra Leone. Microb Drug Resist 1997, 3:195-197. 10.1089/mdr.1997.3.195, 9185147.
14. Kapur V, Li LL, Iordanescu S, Hamrick MR, Wanger A, Kreiswirth BN, Musser JM. Characterization by automated DNA sequencing of mutations in the gene (rpoB) encoding the RNA polymerase β subunit in rifampin-resistant Mycobacterium tuberculosis strains from New York City and Texas. J Clin Microbiol 1994, 32:1095-1098. 267194, 8027320.
15. Huang WL, Chen HY, Kuo YM, Jou R. Performance assessment of the GenoType MTBDRplus test and DNA sequencing in detection of multidrug-resistant Mycobacterium tuberculosis. J Clin Microbiol 2009, 47:2520-2524. 10.1128/JCM.02499-08, 2725636, 19494067.
16. Nikolayevskyy V, Balabanova Y, Simak T, Malomanova N, Fedorin I, Drobniewski F. Performance of the Genotype® MTBDRplus assay in the diagnosis of tuberculosis and drug resistance in Samara, Russian Federation. BMC Clin Pathol 2009, 9:2. 10.1186/1472-6890-9-2, 2660363, 19284561.
17. Revised National Tuberculosis Control Programme (RNTCP) DOTS Plus Guidelines. 2010, Revised National Tuberculosis Control Programme (RNTCP).
18. D'souza DTB, Mistry NF, Vira TS, Dholakia Y, Hoffner S, Pasvol G, Nicol M, Wilkinson RJ. High levels of multidrug resistant tuberculosis in new and treatment-failure patients from the Revised National Tuberculosis Control Programme in an urban metropolis (Mumbai) in Western India. BMC Publ Health 2009, 9:211.
19. Rodrigues C, Shenai S, Sadani M, Thakkar P, Sodha A, Udwadia ZF, Mahashur A, Soman R, Mehta A. Multi drug-resistant tuberculosis in Mumbai: it's only getting worse. Int J Tuberc Lung Dis 2006, 10:1421-1422.
20. Almeida D, Rodrigues C, Udwadia ZF, Lalvani A, Gothi GD, Mehta P, Mehta A. Incidence of multidrug-resistant tuberculosis in urban and rural India and implications for prevention. Clin Infect Dis 2003, 36:152-154.
21. Chowgule RV, Lina D. Pattern of secondary acquired drug resistance to antituberculosis drugs in Mumbai, India 1991-1995. Ind J Chest Dis Allied Sciences 1998, 40:23-31.
22. Baker JF, Silverton RE. Routine bacteriological examination of specimens. Introduction to medical laboratory technology 1978, 528-530. London: Butterworths, 5.
23. National Committee on Clinical and Laboratory Standards Susceptibility testing of Mycobacteria, Nocardia and other aerobic Actinomycetes. Tentative standard. 2000, 2, M24-T2, NCCLS, National Committee on Clinical and Laboratory Standards.
24. Shah DH, Devdhar MN, Ganatra RD, Kale PN, Virdi SS, Deshmukh MD. Modified rapid radiometric method for detection of Mycobacterium tuberculosis from sputum samples. Int J Nucl Med Biol 1985, 12:333-335. 10.1016/0047-0740(85)90190-1, 3936813.
25. van Soolingen D, Hermans PWM, de Haas PEW, Soll DR, van Embden JDA. The occurrence and stability of insertion sequences in Mycobacterium tuberculosis complex strains; evaluation of IS-dependent DNA polymorphism as a tool in the epidemiology of tuberculosis. J Clin Microbiol 1991, 29:2578-2586. 270376, 1685494.
26. Kirkwood BR, Sterne JAC. Measurement error: assessment and implications. Essential Medical Statistics 2003, 429-446. Blackwell Science, Inc., Massachusetts 02148-5020, USA, 2.
27. Lacoma A, Garcia-Sierra N, Prat C, Ruiz-Manzano J, Haba L, Roses S, Maldonado J, Dominguez J. GenoType MTBDRplus assay for molecular detection of rifampin and isoniazid resistance in Mycobacterium tuberculosis strains and clinical samples. J Clin Microbiol 2008, 46:3660-3667. 10.1128/JCM.00618-08, 2576567, 18784319.
28. Traore H, Ogwang S, Mallard K, Joloba ML, Mumbowa F, Narayan K, Kayes S, Jones-Lopez EC, Smith PG, Ellner JJ, Mugerwa RD, Eisenach KD, McNerney R. Low-cost rapid detection of rifampicin resistant tuberculosis using bacteriophage in Kampala, Uganda. Ann Clin Microbiol Antimcrob 2007, 6:1-6.
29. Ma X, Wang H, Deng Y, Liu Z, Xu Y, Pan X, Musser JM, Graviss EA. rpoB gene mutations and molecular characterization of rifampin-resistant Mycobacterium tuberculosis isolates from Shandong Province, China. J Clin Microbiol 2006, 44:3409-3412. 10.1128/JCM.00515-06, 1594713, 16954287.
30. Rinder H, Mieskes KT, Löscher T. Heteroresistance in Mycobacterium tuberculosis. Int J Tuberc Lung Dis 2001, 5:339-345.
31. Hofmann-Thiel S, van Ingen J, Feldmann K, Turaev L, Uzakova GT, Murmusaeva G, van Soolingen D, Hoffmann H. Mechanisms of heteroresistance to isoniazid and rifampin of Mycobacterium tuberculosis in Tashkent, Uzbekistan. Eur Respir J 2009, 33:368-374.
32. Colijn C, Cohen T, Ganesh A, Murray M. Spontaneous Emergence of Multiple Drug Resistance in Tuberculosis before and during Therapy. PloS ONE 2011, 6(3):e18327. 10.1371/journal.pone.0018327, 3068161, 21479171.
33. Hazbón MH, Brimacombe M, del Valle MB, Cavatore M, Guerrero ML, Varma-Basil M, Billman-Jacobe H, Lavender C, Fyfe J, García-García L, León CI, Bose M, Chaves F, Murray M, Eisenach KD, Sifuentes-Osornio J, Cave MD, de León AP, Alland D. Population genetics study of isoniazid resistance mutations and evolution of multidrug-resistant Mycobacterium tuberculosis. Antimicrob Agents Chemother 2006, 50:2640-2649. 10.1128/AAC.00112-06, 1538650, 16870753.
34. Lee ASG, Lim IHK, Tang LLH, Telenti A, Wong SY. Contribution of kasA analysis to detection of isoniazid-resistant Mycobacterium tuberculosis in Singapore. Antimicrob Agents Chemother 1999, 43:2087-2089. 89423, 10428945.
35. Marttila HJ, Soini H, Eerola E, Vyshnevskaya E, Vyshnevskiy BL, Otten TF, Vasilyef AV, Viljanen MK. A Ser315Thr substitution in KatG is predominant in genetically heterogeneous multidrug-resistant Mycobacterium tuberculosis isolates originating from the St. Petersburg area in Russia. Antimicrob Agents Chemother 1998, 42:2443-2445. 105851, 9736581.
36. Causse M, Ruiz P, Gutierrez JB, Zerolo J, Casal M. Evaluation of new GenoType® MTBDRplus for detection of resistance in cultures and direct specimens of Mycobacterium tuberculosis. Int J Tuberc Lung Dis 2008, 12:1456-1460.
37. Evans J, Stead MC, Nicol MP, Segal H. Rapid genotypic assays to identify drug-resistant Mycobacterium tuberculosis in South Africa. J Antimicrob Chemother 2009, 63:11-16.
38. Bolotin S, Alexander DC, Chedore P, Drews SJ, Jamieson F. Molecular characterization of drug-resistant Mycobacterium tuberculosis isolates from Ontario, Canada. J Antimicrob Chemother 2009, 64:263-266. 10.1093/jac/dkp183, 19520719.
39. Kapetanaki SM, Chouchane S, Yu S, Zhao X, Magliozzo RS, Schelvis JP. Mycobacterium tuberculosis KatG (S315T) catalase-peroxidase retains all active site properties for proper catalytic function. Biochemistry 2005, 44:243-252. 10.1021/bi048097f, 15628865.
40. Wei CJ, Lei B, Musser JM, Tu SC. Isoniazid activation defects in recombinant Mycobacterium tuberculosis catalase-peroxidase (KatG) mutants evident in InhA inhibitor production. Antimicrob Agents Chemother 2003, 47:670-675. 10.1128/AAC.47.2.670-675.2003, 151726, 12543676.
41. Saint-Joanis B, Souchon H, Wilming M, Johnsson K, Alzari PM, Cole ST. Use of site-directed mutagenesis to probe the structure, function and isoniazid activation of the catalase-peroxidase, KatG, from Mycobacterium tuberculosis. Biochem J 1999, 338:753-760. 10.1042/0264-6021:3380753, 1220113, 10051449.
42. Richardson ET, Lin SYG, Pinsky BA, Desmond E, Banaei N. First documentation of isoniazid reversion in Mycobacterium tuberculosis. Int J Tuberc Lung Dis 2009, 13:1347-1354.
43. Alland D, Steyn AJ, Weisbrod T, Aldrich K, Jacobs WR. Characterization of the Mycobacterium tuberculosis iniBAC Promoter, a promoter that responds to cell wall biosynthesis inhibition. J Bacteriol 2000, 182:1802-1811. 10.1128/JB.182.7.1802-1811.2000, 101861, 10714983.
44. Colangeli R, Helb D, Sridharan S, Sun J, Varma-Basil M, Hazbón MH, Harbacheuski R, Megjugorac NJ, Jacobs WR, Holzenburg A, Sacchettini JC, Alland D. The Mycobacterium tuberculosis iniA gene is essential for activity of an efflux pump that confers drug tolerance to both isoniazid and ethambutol. Mol Microbiol 2005, 55:1829-1840. 10.1111/j.1365-2958.2005.04510.x, 15752203.
45. Parsons LM, Salfinger M, Clobridge A, Dormandy J, Mirabello L, Polletta VL, Sanic A, Sinyavskiy O, Larsen SC, Driscoll J, Zickas G, Taber HW. Phenotypic and molecular characterization of Mycobacterium tuberculosis isolates resistant to both isoniazid and ethambutol. Antimicrob Agents Chemother 2005, 49:2218-2225. 10.1128/AAC.49.6.2218-2225.2005, 1140517, 15917515.
46. van Doorn HR, de Haas PEW, Kremer K, Vandenbroucke-Grauls CMJE, Borgdorff MW, van Soolingen D. Public health impact of isoniazid-resistant Mycobacterium tuberculosis strains with a mutation at amino-acid position 315 of katG: a decade of experience in The Netherlands. Clin Microbiol Infect 2006, 12:769-775.
47. Gagneux S, Long CD, Small PM, Van T, Schoolnik GK, Bohannan BJM. The competitive cost of antibiotic resistance in Mycobacterium tuberculosis. Science 2006, 312:1944-1946. 10.1126/science.1124410, 16809538.
48. Siddiqi N, Shamim M, Hussain S, Choudhary RK, Ahmed N, Prachee, Banerjee S, Savithri GR, Alam M, Pathak N, Amin A, Hanief M, Katoch VM, Sharma SK, Hasnain SE. Molecular characterization of multidrug-resistant isolates of Mycobacterium tuberculosis from patients in north India. Antimicrob Agents Chemother 2002, 46:443-450. 10.1128/AAC.46.2.443-450.2002, 127030, 11796356.
49. Rattan A, Kalia A, Ahmed N. Multidrug-resistant Mycobacterium tuberculosis: molecular perspectives. Ind J Tub 1999, 46:51-68.